{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:06:24Z","timestamp":1792112784069,"version":"4.4.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000064","name":"Banting and Best Diabetes Centre, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018679","name":"HLS Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Antipsychotic-induced dyslipidemia represents a common adverse effect faced by patients with schizophrenia that increases risk for developing further metabolic complications and cardiovascular disease. Despite its burden, antipsychotic-induced dyslipidemia is often left untreated, and the effectiveness of pharmacological interventions for mitigating dyslipidemia has not been well-addressed. This review aims to assess the effectiveness of pharmacological interventions in alleviating dyslipidemia in patients with schizophrenia.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Medline, PsychInfo, and EMBASE were searched for all relevant English articles from 1950 to November 2020. Randomized placebo-controlled trials were included. Differences in changes in triglycerides, HDL cholesterol, LDL cholesterol, and VLDL cholesterol levels between treatment and placebo groups were meta-analyzed as primary outcomes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Our review identified 48 randomized controlled trials that comprised a total of 3,128 patients and investigated 29 pharmacological interventions. Overall, pharmacological interventions were effective in lowering LDL cholesterol, triglycerides, and total cholesterol levels while increasing the levels of HDL cholesterol. Within the intervention subgroups, approved lipid-lowering agents did not reduce lipid parameters other than total cholesterol level, while antipsychotic switching and antipsychotic add-on interventions improved multiple lipid parameters, including triglycerides, LDL cholesterol, HDL cholesterol, and total cholesterol. Off label lipid lowering agents improved triglycerides and total cholesterol levels, with statistically significant changes seen with metformin.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Currently available lipid lowering agents may not work as well in patients with schizophrenia who are being treated with antipsychotics. Additionally, antipsychotic switching, antipsychotic add-ons, and certain off label interventions might be more effective in improving some but not all associated lipid parameters. Future studies should explore novel interventions for effectively managing antipsychotic-induced dyslipidemia.<\/jats:p><jats:p><jats:bold>Registration:<\/jats:bold> PROSPERO 2020 CRD42020219982; <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020219982<\/jats:ext-link>.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.642403","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T04:41:34Z","timestamp":1615956094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Pruntha","family":"Kanagasundaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femin","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya A.","family":"Costa-Dookhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"B1","volume-title":"Global Status Report on Noncommunicable Diseases 2014","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.psychres.2012.02.019","article-title":"Impaired plasmalogens in patients with schizophrenia","volume":"198","author":"Kaddurah-Daouk","year":"2012","journal-title":"Psychiatry Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1021\/pr800188y","article-title":"High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides","volume":"7","author":"Schwarz","year":"2008","journal-title":"J Proteome Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1192\/bjp.184.47.s76","article-title":"Metabolic disturbance in first-episode schizophrenia","volume":"47","author":"Thakore","year":"2004","journal-title":"Br J Psychiatry Suppl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4088\/JCP.08m04508","article-title":"Metabolic risk factors in drug-naive patients with first-episode psychosis","volume":"70","author":"Verma","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fpsyt.2020.00775","article-title":"Glucose metabolism, thyroid function, and prolactin level in adolescent patients with first episode of schizophrenia and affective disorders","volume":"11","author":"Petruzzelli","year":"2020","journal-title":"Front Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/S0033291798008186","article-title":"The unhealthy lifestyle of people with schizophrenia","volume":"29","author":"Brown","year":"1999","journal-title":"Psychol Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.schres.2004.04.007","article-title":"Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia","volume":"75","author":"Strassnig","year":"2005","journal-title":"Schizophr Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.2174\/1381612821666150619092903","article-title":"Off-Label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends","volume":"21","author":"Carton","year":"2015","journal-title":"Curr Pharm Des."},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1600-0447.2004.00372.x","article-title":"Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs","volume":"110","author":"Paton","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"B12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0447.2004.00358.x","article-title":"Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey","volume":"118","author":"Saari","year":"2004","journal-title":"Acta Psychiatr Scand."},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline","volume":"86","author":"Nasrallah","year":"2006","journal-title":"ResSchizophr Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1176\/ps.2010.61.9.892","article-title":"Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients","volume":"61","author":"Correll","year":"2010","journal-title":"Psychiatr Serv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/YIC.0b013e32834a5bf6","article-title":"The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs","volume":"26","author":"Falissard","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain","volume":"162","author":"Henderson","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/schbul\/22.3.413","article-title":"Medical comorbidity in schizophrenia","volume":"22","author":"Jeste","year":"1996","journal-title":"Schizophr Bull"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1586\/ern.10.85","article-title":"Management of antipsychotic-related weight gain","volume":"10","author":"Maayan","year":"2010","journal-title":"Expert Rev Neurother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0920-9964(14)70289-0","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis","volume":"40","author":"Mizuno","year":"2014","journal-title":"Schizophr Bull"},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/2042018812458697","article-title":"Interventions for the metabolic syndrome in schizophrenia: a review","volume":"3","author":"Papanastasiou","year":"2012","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0269881107077815","article-title":"Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents","volume":"22","author":"Ojala","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.4088\/JCP.v67n1208","article-title":"Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder","volume":"67","author":"De Hert","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B24","first-page":"141","article-title":"An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics","volume":"25","author":"Vincenzi","year":"2013","journal-title":"Ann Clin Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/JCP.0b013e3181727592","article-title":"Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study","volume":"28","author":"Landry","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.psychres.2017.12.028","article-title":"Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate","volume":"261","author":"Behdani","year":"2018","journal-title":"Psychiatry Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.psychres.2007.06.029","article-title":"Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial","volume":"161","author":"Emsley","year":"2008","journal-title":"Psychiatry Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.schres.2018.09.006","article-title":"A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone","volume":"204","author":"Robinson","year":"2019","journal-title":"Schizophr Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.schres.2014.08.021","article-title":"A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism","volume":"159","author":"Vincenzi","year":"2014","journal-title":"Schizophr Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00213-018-5136-9","article-title":"Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial","volume":"236","author":"Xu","year":"2019","journal-title":"Psychopharmacology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/0269881111430748","article-title":"Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study","volume":"26","author":"Chen","year":"2012","journal-title":"J Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/acps.12009","article-title":"Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia","volume":"127","author":"Fan","year":"2013","journal-title":"Acta Psychiatr Scand."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int J Neuropsychopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2147\/NDT.S80925","article-title":"Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study","volume":"11","author":"Wani","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0139717","DOI":"10.1371\/journal.pone.0139717","article-title":"Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS ONE."},{"key":"B39","unstructured":"Chapter 7: selecting studies and collecting data. In: Higgins JP, Green S, editors\n            HigginsJP\n            GreenS\n          Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.2011"},{"key":"B40","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2147\/TCRM.S3153","article-title":"Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder","volume":"4","author":"Deberdt","year":"2008","journal-title":"Ther Clin Risk Manag."},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","article-title":"Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial","volume":"93","author":"Baptista","year":"2007","journal-title":"Schizophr Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","article-title":"Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study","volume":"113","author":"Carrizo","year":"2009","journal-title":"Schizophr Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.4088\/JCP.12m08186","article-title":"Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study","volume":"74","author":"Chen","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0168347","DOI":"10.1371\/journal.pone.0168347","article-title":"Effects of low dose metformin on metabolic traits in clozapine-treated schizophrenia patients: an exploratory twelve-week randomized, double-blind, placebo-controlled study","volume":"11","author":"Chiu","year":"2016","journal-title":"PLoS ONE."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","article-title":"Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder","volume":"170","author":"Jarskog","year":"2013","journal-title":"Am J Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/mp.2015.221","article-title":"Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials","volume":"21","author":"Wu","year":"2016","journal-title":"Mol Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00213-013-3199-1","article-title":"The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients","volume":"230","author":"Amrami-Weizman","year":"2013","journal-title":"Psychopharmacology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/S1516-44462006000400005","article-title":"Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine","volume":"28","author":"Assun\u00e7\u00e3o","year":"2006","journal-title":"Braz J Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3371\/CSRP.5.1.3","article-title":"Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine","volume":"5","author":"Ball","year":"2011","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"B51","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-0028-1085438","article-title":"Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled 12-week trial","volume":"42","author":"Baptista","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1600-0447.2008.01325.x","article-title":"A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia","volume":"119","author":"Henderson","year":"2009","journal-title":"Acta Psychiatr Scand."},{"key":"B54","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/JCP.0b013e31822bb573","article-title":"Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia","volume":"31","author":"Borba","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00213-019-5181-z","article-title":"Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial","volume":"236","author":"Fan","year":"2019","journal-title":"Psychopharmacology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12888-019-2059-x","article-title":"Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients","volume":"19","author":"Ghaderi","year":"2019","journal-title":"BMC Psychiatry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1600-0447.2006.00855.x","article-title":"A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain","volume":"115","author":"Henderson","year":"2007","journal-title":"Acta Psychiatr Scand."},{"key":"B58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.12740\/PP\/30180","article-title":"The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine\u2014a randomized, double-blind trial","volume":"49","author":"Holka-Pokorska","year":"2015","journal-title":"Psychiatr Pol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"B60","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4088\/JCP.v69n0503","article-title":"Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial","volume":"69","author":"Joffe","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ebiom.2017.11.027","article-title":"Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Krivoy","year":"2017","journal-title":"EBioMedicine."},{"key":"B62","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.schres.2013.01.034","article-title":"No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia","volume":"146","author":"Li","year":"2013","journal-title":"Schizophr Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JCP.0000000000000841","article-title":"No effect of adjunctive minocycline treatment on body metabolism in patients with schizophrenia","volume":"38","author":"Liu","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.schres.2017.06.030","article-title":"Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"766","DOI":"10.4088\/JCP.v65n0607","article-title":"Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances","volume":"65","author":"Lu","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fphar.2018.00181","article-title":"Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia","volume":"9","author":"Lyu","year":"2018","journal-title":"Front Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jpsychires.2014.02.013","article-title":"Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study","volume":"53","author":"Modabbernia","year":"2014","journal-title":"J Psychiatr Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bdi.12196","article-title":"Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial","volume":"16","author":"Romo-Nava","year":"2014","journal-title":"Bipolar Disord."},{"key":"B70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.10.023","article-title":"Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study","volume":"143","author":"Smith","year":"2013","journal-title":"Schizophr Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"5103046","DOI":"10.1155\/2020\/5103046","article-title":"A placebo-controlled study on the treatment of metabolic syndrome of qi stagnation and dampness obstruction related to atypical antipsychotics with traditional chinese medicine (TCM)","volume":"2020","author":"Sun","year":"2020","journal-title":"Evid Based Complement Alternat Med."},{"key":"B72","first-page":"1118","article-title":"A comparison on composition of celery, dill and green tea as three medicinal plants with placebo to treat schizophrenia patients' metabolic syndrome","volume":"80","author":"Tavakoli","year":"2014","journal-title":"Afinidad."},{"key":"B73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/0269881113509904","article-title":"The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study","volume":"28","author":"Taveira","year":"2014","journal-title":"J Psychopharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/JCP.0000000000000192","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept","volume":"34","author":"Tek","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"505","DOI":"10.6133\/apjcn.202009_29(3).0009","article-title":"Beneficial effects of konjac powder on lipid profile in schizophrenia with dyslipidemia: a randomized controlled trial","volume":"29","author":"Zhang","year":"2020","journal-title":"Asia Pac J Clin Nutr."},{"key":"B76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/nu8020073","article-title":"Resveratrol supplementation in schizophrenia patients: a randomized clinical trial evaluating serum glucose and cardiovascular risk factors","volume":"8","author":"Zortea","year":"2016","journal-title":"Nutrients."},{"key":"B77","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41398-020-0785-y","article-title":"Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"10","author":"Jiang","year":"2020","journal-title":"Transl Psychiatry."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation."},{"key":"B80","doi-asserted-by":"publisher","first-page":"PCC.11r01298","DOI":"10.4088\/PCC.11r01298","article-title":"Review of the safety of second-generation antipsychotics: are they really \u201catypically\u201d safe for youth and adults?","volume":"14","author":"Briles","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"B81","doi-asserted-by":"publisher","first-page":"CD006569","DOI":"10.1002\/14651858.CD006569.pub3","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"573479","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.euroneuro.2008.02.002","article-title":"Management of physical health in schizophrenia: a stepping stone to treatment success","volume":"18","author":"Millar","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12913-020-05654-z","article-title":"Examining healthcare professionals' beliefs and actions regarding the physical health of people with schizophrenia","volume":"20","author":"Berry","year":"2020","journal-title":"BMC Health Serv Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2190\/PM.41.4.g","article-title":"Barriers to metabolic care for adults with serious mental illness: provider perspectives","volume":"41","author":"McDonell","year":"2011","journal-title":"Int J Psychiatry Med."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.642403\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T04:41:58Z","timestamp":1615956118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.642403\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":85,"alternative-id":["10.3389\/fpsyt.2021.642403"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.642403","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"article-number":"642403"}}